Ingenia Therapeutics expects USD 5 million milestone payment from Merck unit Eyebiotech
Payment is tied to MK-8748 and was triggered by the start of a global Phase 3 trial in diabetic macular edema.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.